Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Clinical trial NCT06243354 · RECRUITING
Trial details
- NCT number
- NCT06243354
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-04
- Primary completion
- 2026-12-01
- Enrollment
- 257
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.